High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells

World Journal of Gastroenterology

Volumn 11, Issue 7, 2005, Pages 954-959

  Lou, Bin ^a   Liao, Xue Ling ^a   Wu, Man Ping ^a   Cheng, Pei Fang ^a   Yin, Chun Yan ^a   Fei, Zheng ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Antitumoral drug; Carrier; High density lipoprotein; SMMC 7721 hepatoma cell

Indexed keywords

ACLACINOMYCIN; ANTINEOPLASTIC AGENT; APOPROTEIN; DRUG CARRIER; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE;

ARTICLE; BINDING AFFINITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG PURITY; GEL MOBILITY SHIFT ASSAY; HEPATOMA CELL; HUMAN; HUMAN CELL; LIPOPHILICITY; LIVER CELL; MORPHOLOGY; PARTICLE SIZE; PHYSICAL PARAMETERS; PROTEIN STRUCTURE;

EID: 14844282055     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i7.954     Document Type: Article

References (33)

1. Firestone RA. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug Chem 1994; 5: 105-113
2. de Smidt PC, van Berkel TJ. LDL-mediated drug targeting. Crit Rev Ther Drug Carrier Syst 1990; 7: 99-120
3. Janknegt R. Liposomal formulations of cytotoxic drugs. Support Care Cancer 1996; 4: 298-304
4. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994; 15: 42-52
5. Tokui T, Kuroiwa C, Muramatsu S, Tokui Y, Sasagawa K, Ikeda T, Komai T. Plasma lipoproteins as targeting carriers to tumour tissues after administration of a lipophilic agent to mice. Biopharm Drug Dispos 1995; 16: 91-103
6. Hauser H, Kostner GM. Structural organization of free and esterified cholesterol in human high density lipoproteins. A 100.6 MHz 13C NMR study. Biochim Biophys Acta 1979; 573: 375-381
7. Samadi-Baboli M, Favre G, Canal P, Soula G. Low density lipoprotein for cytotoxic drug targeting: Improved activity of elliptinium derivative against B16 melanoma in mice. Br J Cancer 1993; 68: 319-326
8. Kader A, Davis PJ, Kara M, Liu H. Drug targeting using low density lipoprotein (LDL): Physicochemical factors affecting drug loading into LDL particles. J Control Release 1998; 55: 231-243
9. Filipowska D, Filipowski T, Morelowska B, Kazanowska W, Laudanski T, Lapinjoki S, Akerlund M, Breeze A: Treatment of cancer patients with a low-density-lipoprotein delivery vehicle containing a cytotoxic drug. Cancer Chemother Pharmacol 1992; 29: 396-400
10. Pussinen PJ, Lindner H, Glatter O, Reicher H, Kostner GM, Wintersperger A, Malle E, Sattler W. Lipoprotein-associated alpha-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBl-100 breast cancer cells. Biochim Biophys Acta 2000 1485: 129-144
11. Lenz M, Miehe WP, Vahrenwald F, Bruchelt G, Schweizer P, Girgert R. Cholesterol based antineoplastic strategies. Anticancer Res 1997; 17: 1143-1146
12. Kader A, Pater A. Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J Control Release 2002; 80: 29-44
13. Masquelier M, Tirzitis G, Peterson CO, Palsson M, Amolins A, Plotniece M, Plotniece A, Makarova N, Vitols SG. Plasma stability and cytotoxicity of lipophilic daunorubicin derivatives incorporated into low density lipoproteins. Eur J Med Chem 2000; 35: 429-438
14. Masquelier M, Vitols S, Palsson M, Mars U, Larsson BS, Peterson CO. Low density lipoprotein as a carrier of cytostatics in cancer chemotherapy: Study of stability of drug-carrier complexes in blood. J Drug Target 2000; 8: 155-164
15. Masquelier. Method for the production of a macromolecular carrier loaded with a biologically active substance. United States Patent 1989; September 19
16. Lundberg B. Assembly of prednimustine low-density-lipoprotein complexes and their cytotoxic activity in tissue culture. Cancer Chem Pharmacol 1992; 29: 241-247
17. Xiao W, Wang L, Ryan JM, Pater A, Liu H. Incorporation of an (125)I-labeled hexa-iodinated diglyceride analog into low-density lipoprotein and high specific uptake by cells of cervical carcinoma cell lines. Radiat Res 1999; 152: 250-256
18. Goldstein JL, Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 1977; 46: 897-930
19. Lundberg B, Suominen L. Preparation of biologically active analogs of serum low-density lipoprotein. J Lipid Res 1984; 25: 550-558
20. Bijsterbosch MK, Schouten D, van Berkel TJ. Synthesis of the dioleoyl derivative of iododeoxyuridine and its incorporation into reconstituted high density lipoprotein particles. Biochemistry 1994; 33: 14073-14080
21. Pieters MN, Schouten D, Van Berkel TJ. In vitro and in vivo evidence for the role of HDL in reverse cholesterol transport. Biochim Biophys Acta 1994; 1225: 125-134
22. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996; 271: 518-520
23. Acton SL, Kozarsky KF, Rigotti A. The HDL receptor SR-BI: A new therapeutic target for atherosclerosis? Mol Med Today 1999; 5: 518-524
24. Rinninger F, Brundert M, Budzinski RM, Fruchart JC, Greten H, Castro GR. Scavenger receptor BI (SR-BI) mediates a higher selective cholesteryl ester uptake from lpA-I compared with lpA-I:A-II lipoprotein particles. Atherosclerosis2003; 166: 31-40
25. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, Champagne E, Pineau T, Georgeaud V, Walker JE, Terce F, Collet X, Perret B, Barbaras R. Ectopic β-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003; 421: 75-79
26. 2-CE by rat hepatic sinusoidal cells. Shengwu Huaxue Yu Wuli Xuebao 1996; 28: 659-663
27. Shaw JM, Shaw KV, Yanovich S, Iwanik M, Futch WS, Rosowsky A, Schook LB. Delivery of lipophilic drugs using lipoproteins. Ann N Y Acad Sci 1987; 507: 252-271
28. Schumaker VN, Puppione DL. Sequential flotation ultracentrifugation. Methods Enzymol 1986; 128: 155-170
29. Scanu A. Forms of human serum high density lipoprotein protein. J Lipid Res 1966; 7: 295-306
30. Pittman RC, Glass CK, Atkinson D, Small DM. Synthetic high density lipoprotein particles. Application to studies of the apoprotein specificity for selective uptake of cholesterol esters. J Biol Chem 1987; 262: 2435-2442
31. Eklund A, Sjoblom L. Improved banding pattern of rat plasma lipoproteins developed by agarose gel electrophoresis at pH 7.0. Biochim Biophys Acta 1986; 877: 135-140
32. Jabbar SA, Twentyman PR, Watson JV. The MTT assay underestimates the growth inhibitory effects of interferons. Br J Cancer 1989; 60: 523-528
33. Rensen PC, de Vrueh RL, Kuiper J, Bijsterbosch MK, Biessen EA, van Berkel TJ. Recombinant lipoproteins: Lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 2001; 47: 251-276